Real-world reductions in migraine and headache days after initiating fremanezumab for US patients with migraine and prior use of another monoclonal antibody targeting the CGRP pathway

被引：0
|
作者：
Driessen, M. T. [1 ]
Patterson-Lomba, O. [2 ]
Mu, F. [2 ]
Thompson, S. F. [3 ]
Seminerio, M. J. [4 ]
Carr, K. [4 ]
Sun, R. [2 ]
Totev, T. [2 ]
Yim, E. [2 ]
Ayyagari, R. [5 ]
Cohen, J. M. [4 ]
机构：
[1] Teva Pharmaceut, Amsterdam, Netherlands
[2] Anal Grp, Boston, MA USA
[3] Teva Branded Pharmaceut Prod R&D Inc, Parsippany, NJ USA
[4] Teva Branded Pharmaceut Prod R&D Inc, W Chester, PA USA
[5] Anal Grp Inc, Boston, MA USA
来源：
HEADACHE | 2021年 / 61卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P-165
引用
收藏
页码：141 / 141
页数：1
相关论文
共 50 条
  • [31] Reductions in migraine and headache days in chronic migraine patients with and without prior migraine preventive treatment use: Subgroup analysis of the HALO CM study
    Jenkins, B.
    Cohen, J. M.
    Yang, R.
    Ramirez-Campos, V.
    [J]. JOURNAL OF THE NEUROLOGICAL SCIENCES, 2019, 405
  • [32] Real-world evidence for the safety and efficacy of CGRP monoclonal antibody therapy added to OnabotulinumtoxinA treatment for migraine prevention in adult patients with chronic migraine
    Mechtler, L. L.
    Saikali, N. P.
    McVige, J.
    Hughes, O.
    Traut, A.
    Adams, A.
    [J]. HEADACHE, 2021, 61 : 176 - 177
  • [33] Real-World Evidence for the Safety and Efficacy of CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA Treatment for Migraine Prevention in Adult Patients With Chronic Migraine
    Mechtler, Laszlo
    Saikali, Nicolas
    McVige, Jennifer
    Hughes, Olivia
    Traut, Alexandra
    Adams, Aubrey
    [J]. TOXICON, 2022, 214 : S39 - S40
  • [34] Real-world Evidence for the Safety and Efficacy of CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA Treatment for Migraine Prevention in Adult Patients with Chronic Migraine
    Mechtler, L.
    Saikali, N.
    McVige, J.
    Hughes, O.
    Traut, A.
    Adams, A.
    [J]. JOURNAL OF HEADACHE AND PAIN, 2021, 22 (SUPPL 1): : 48 - 49
  • [35] Real-world Evidence for the Safety and Efficacy of CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA Treatment for Migraine Prevention in Adult Patients with Chronic Migraine
    Mechtler, L.
    Saikali, N.
    McVige, J.
    Hughes, O.
    Traut, A.
    Adams, A.
    [J]. CEPHALALGIA, 2021, 41 (1_SUPPL) : 74 - 74
  • [36] Real-World Evidence for the Safety and Efficacy of CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA Treatment for Migraine Prevention in Adult Patients With Chronic Migraine
    Mechtler, Laszlo
    Saikali, Nicolas
    McVige, Jennifer
    Hughes, Olivia
    Traut, Alexandra
    Adams, Aubrey Manack
    [J]. FRONTIERS IN NEUROLOGY, 2022, 12
  • [37] Real-world effectiveness of fremanezumab in patients with refractory migraine from a US tertiary headache center who switched from erenumab
    Yuan, H.
    Hopkins, M.
    Driessen, M. T.
    Krasenbaum, L. J.
    Seminerio, M. J.
    Marmura, M. J.
    [J]. HEADACHE, 2022, 62 : 156 - 157
  • [38] REAL-WORLD REDUCTIONS IN MIGRAINE-RELATED HEALTH CARE RESOURCE UTILIZATION AND COSTS FOR PATIENTS INITIATING FREMANEZUMAB: A 12-MONTH RETROSPECTIVE US CLAIMS ANALYSIS
    Driessen, M. T.
    Krasenbaum, L. J.
    Ramirez-Campos, V
    DiEgidio, R.
    Tian, M.
    Seminerio, M. J.
    [J]. VALUE IN HEALTH, 2022, 25 (07) : S346 - S346
  • [39] Real-world migraine-related health care resource utilization and costs for patients initiating fremanezumab: A US retrospective claims analysis
    Buse, D. C.
    Seminerio, M. J.
    Tangirala, K.
    Thompson, S. F.
    Ariely, R.
    Cohen, J. M.
    Carr, K.
    [J]. HEADACHE, 2021, 61 : 71 - 72
  • [40] REAL WORLD IMPACT OF FREMANEZUMAB TREATMENT ON HEADACHE FREQUENCY AND HEALTHCARE RESOURCE USE AMONG US PATIENTS WITH EPISODIC OR CHRONIC MIGRAINE
    McAllister, P.
    Casciano, J.
    Cohen, J.
    Thompson, S.
    Krasenbaum, L.
    Dotiwala, Z.
    Tangirala, K.
    Lamerato, L.
    [J]. VALUE IN HEALTH, 2020, 23 : S640 - S640
12345